Funding for this research was provided by:
Received: 17 August 2021
Revised: 26 November 2021
Accepted: 29 November 2021
First Online: 7 December 2021
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study described has been carried out in accordance with abovementioned standards and has been approved by the Ethics Committee of Medical Faculty of Rostock University, Germany (Ethics approval number: A 2019–0145).
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable.
: AB reports grants from UCB Pharma GmbH and honoraria for speaking engagements from Biogen GmbH, Desitin Arzneimittel GmbH, Eisai GmbH, GW Pharma GmbH, Neuraxpharm GmbH, Shire/Takeda GmbH, UCB Pharma GmbH, and ViroPharma GmbH. The other authors declare no competing interests.